Satellos Bioscience Inc. (TSE:MSCL) has released an update.
Satellos Bioscience Inc. announced its year-end financial results, revealing a strong cash position of $39.6 million and significant progress in its transition to a preclinical company. The company has engaged a CRO for the Phase 1 study of its lead drug candidate, SAT-3247, and is on track to start first-in-human trials by mid-2024. Moreover, recent preclinical studies have shown SAT-3247’s potential to significantly improve muscle function in various models of muscle degeneration.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
